Monoclonal antibodies for cancer immunotherapy
The Lancet, ISSN: 0140-6736, Vol: 373, Issue: 9668, Page: 1033-1040
2009
- 264Citations
- 287Captures
- 2Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations264
- Citation Indexes263
- 263
- CrossRef212
- Patent Family Citations1
- Patent Families1
- Captures287
- Readers287
- 287
- Mentions2
- News Mentions1
- News1
- References1
- Wikipedia1
Most Recent News
Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma; Inbraced
STUDY INFORMATION OFFICIAL TITLE: A Phase I Study of 131-1 Meta-iodobenzylguanidine (mIBG) Followed by Nivolumab and Chimeric 14.18 Anti-GD2 Monoclonal Antibody Produced in Chinese Hamster
Review Description
Monoclonal antibodies are effective treatments for many malignant diseases. However, the ability of antibodies to initiate tumour-antigen-specific immune responses has received less attention than have other mechanisms of antibody action. We describe the rationale and evidence for the development of antibodies that can stimulate host tumour-antigen-specific immune responses. Such responses can be induced through the induction of antibody-dependent cellular cytotoxicity, promotion of antibody-targeted cross-presentation of tumour antigens, or by triggering of the idiotypic network. Future treatment modifications or combinations might be able to prolong, amplify, and shape these immune responses to increase the clinical benefits of antibody therapy for human cancer.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0140673609602518; http://dx.doi.org/10.1016/s0140-6736(09)60251-8; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=62349132009&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/19304016; https://linkinghub.elsevier.com/retrieve/pii/S0140673609602518; http://linkinghub.elsevier.com/retrieve/pii/S0140673609602518; http://api.elsevier.com/content/article/PII:S0140673609602518?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0140673609602518?httpAccept=text/plain
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know